Study guide

12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism

Key Takeaways Explain This Topic AI

Low or absent radioiodine uptake with thyrotoxicosis indicates thyroiditis or exogenous thyroxine, not Graves' disease or a toxic nodule.

Carbimazole causes agranulocytosis - any sore throat or fever requires an urgent full blood count and drug cessation - and is teratogenic in the first trimester, where propylthiouracil is preferred.

In thyroid storm, propylthiouracil is given before iodine (Lugol's solution), which must follow the thionamide by at least an hour to avoid substrate loading.

Last updated: September 2026

Thyroid disorders encompass a wide spectrum of functional, autoimmune, and neoplastic pathologies frequently encountered in MRCP(UK) Part 1. Candidates must master the laboratory differentiation of primary, secondary, and subclinical thyroid dysfunction, the aetiological distinction between autonomous hyperfunctioning glands and destructive thyroiditis, evidence-based management across pregnancy and thyroid storm, and the histopathological classification of thyroid malignancies.

  • 1. Hyperthyroidism & Thyrotoxicosis: Aetiology & Investigation
  • Thyrotoxicosis vs. Hyperthyroidism

Thyrotoxicosis: The clinical, physiological, and biochemical syndrome resulting from excess circulating free thyroid hormones (free T4 and/or free T3), regardless of the underlying source.

Hyperthyroidism: Specifically denotes sustained de novo overproduction and hypersecretion of thyroid hormones by a hyperfunctioning thyroid gland.

Primary Aetiologies of Thyrotoxicosis Aetiological Breakdown of Thyrotoxicosis:

- Graves' Disease (~75%): TSH-receptor autoantibodies (TRAb) → Diffuse toxic hyperplasia + Extrathyroidal signs

- Toxic Multinodular Goitre (Plummer's, ~15%): Autonomous functional nodules → Patchy isotope uptake, older patients

- Toxic Solitary Adenoma (~5%): Single somatic mutation (TSHR/Gs-alpha) → Unifocal "hot" nodule with suppressed remainder

- Destructive Thyroiditis (~5%): Release of stored preformed hormone → Very low / suppressed isotope uptake (<1%)

  • Exogenous / Factitious: Ingestion of levothyroxine → Low uptake, undetectable serum thyroglobulin
  • Graves' Disease: Pathognomonic Features

Immunopathogenesis: Caused by circulating immunoglobulin G (IgG) autoantibodies directed against the TSH receptor (TRAb / TSI) on thyroid follicular cells. TRAb binds and constitutively activates the receptor, stimulating cyclic AMP cascades that drive uninhibited thyroid hormone synthesis and diffuse follicular hyperplasia.

Extrathyroidal Manifestations (Specific to Graves'):

Graves' Orbitopathy (Thyroid Eye Disease): Orbital fibroblasts express TSH receptors and IGF-1 receptors. Activation by TRAb triggers T-cell infiltration and synthesis of hydrophilic glycosaminoglycans (hyaluronic acid) by orbital fibroblasts, causing adipogenesis and extraocular muscle oedema (inferior and medial recti most commonly affected). Signs: exophthalmos, chemosis, periorbital fullness, lid retraction (Dalrymple's sign), lid lag (von Graefe's sign), diplopia, and optic nerve compression. Active smoking multiplies the risk and severity by 5- to 8-fold.

Pretibial Myxoedema (Thyroid Dermopathy): Infiltration of glycosaminoglycans into the dermis of the anterolateral lower leg, producing non-pitting, violaceous, indurated plaques with an "orange-peel" (peau d'orange) texture. Almost exclusively seen in patients with severe orbitopathy and very high TRAb titres.

Thyroid Acropachy: Extreme manifestation characterized by digital clubbing, soft-tissue swelling of hands/feet, and periosteal new bone formation.

Thyroid Bruit: Auscultation of a continuous vascular murmur over the thyroid gland reflects intense hypervascularity and high-volume blood flow.

Diagnostic Confirmation: Positive serum TRAb (>95% sensitivity and specificity) ; high-affinity 99mTc-pertechnetate or 123-I isotope scan demonstrates homogenous, diffuse, intensely elevated radiotracer uptake .

Toxic Multinodular Goitre (TMNG) & Toxic Solitary Adenoma

TMNG (Plummer's Disease): Commonest cause of thyrotoxicosis in elderly individuals or areas of borderline iodine deficiency. Arises from somatic activating mutations in the TSH receptor gene within multiple discrete nodules. Characteristically lacks orbitopathy or pretibial myxoedema. Isotope scanning shows heterogeneous, patchy distribution with multiple hot and cold areas .

Toxic Solitary Adenoma: Single autonomous adenoma harboring a clonal activating mutation in TSHR or GNAS genes. Isotope scan reveals a solitary "hot" nodule with complete suppression of radiotracer uptake in the remainder of the normal thyroid parenchyma.

2. Thyroiditis: Comparative Differential Diagnosis

Destructive thyroiditis causes transient thyrotoxicosis through inflammatory necrosis of follicular cells, releasing preformed stored colloid into the systemic circulation. It typically follows a triphasic clinical course: Transient Thyrotoxic Phase (2–6 weeks) → Transient Hypothyroid Phase (2–8 weeks) → Euthyroid Recovery (>90%) .

Condition Pathophysiology & Etiology Clinical Presentation & Physical Signs Diagnostic Autoantibodies Inflammatory Markers (ESR / CRP) Radionuclide Uptake (99mTc / 123-I) Guideline-Directed Pharmacotherapy

Subacute Granulomatous Thyroiditis (de Quervain's / Giant Cell) Post-viral inflammatory reaction (Coxsackie, mumps, adenovirus, enterovirus) in HLA-B35 individuals; granulomatous giant-cell follicular infiltration Exquisitely tender, painful goitre radiating to jaw/ears; preceding viral prodrome; fever, malaise; transient thyrotoxic features Typically negative (or low transient anti-TPO) Markedly elevated: ; ESR often > 50 – 100 mm/h > 50\text{–}100\text{ mm/h} > 50 – 100 mm/h ; CRP high Suppressed / Negligible ( < 1 % < 1\% < 1% uptake) • Symptomatic control: NSAIDs or aspirin ; • Severe cases: oral prednisolone ( 40 mg/day 40\text{ mg/day} 40 mg/day tapered over 4–6w); • Propranolol for thyrotoxic symptoms; • Antithyroid drugs (carbimazole) are completely ineffective

Hashimoto's Thyroiditis (Hashitoxicosis Phase) Autoimmune lymphocytic infiltration with germinal centre formation; early follicular destruction triggers transient thyrotoxicosis Painless, firm, rubbery, bosselated non-tender goitre; transient mild thyrotoxicosis progressing to permanent primary hypothyroidism Anti-TPO antibodies > 90 % > 90\% > 90% ;; Anti-thyroglobulin 60 – 80 % 60\text{–}80\% 60 – 80% Normal or minimally elevated Low, patchy, or normal • Conservative; beta-blocker for symptoms; • Monitor TSH; initiate levothyroxine when hypothyroid phase emerges

Postpartum Thyroiditis Autoimmune destruction occurring within 12 months of delivery; rebound autoimmune activation post-delivery Mild, painless goitre; fatigue; depression; transient thyrotoxic phase (1–3 months post-delivery) followed by hypothyroid phase (3–8 months) Anti-TPO positive in up to 80 % 80\% 80% Normal Suppressed (low uptake) • Propranolol for thyrotoxic phase; • Levothyroxine for symptomatic hypothyroid phase (review at 1 year; ~20–40% progress to permanent hypothyroidism)

Amiodarone-Induced Thyrotoxicosis: Type 1 (AIT-1) Iodine-induced hyperthyroidism (Jod-Basedow phenomenon) in underlying latent Graves' disease or multinodular goitre Non-tender multinodular goitre; thyrotoxic symptoms in patient on amiodarone (releases 6 mg 6\text{ mg} 6 mg free iodine per 200 mg 200\text{ mg} 200 mg tab) TRAb positive (if latent Graves'); anti-TPO variable Normal Low (due to iodine saturation), but Colour Flow Doppler shows hypervascularity • High-dose carbimazole ( 40 – 60 mg/day 40\text{–}60\text{ mg/day} 40 – 60 mg/day ); • May require potassium perchlorate to block iodine transport; • Continue or stop amiodarone in consultation with cardiology

Amiodarone-Induced Thyrotoxicosis: Type 2 (AIT-2) Direct cytotoxic drug-induced destructive thyroiditis causing follicular disruption and colloid leakage in a normal thyroid gland Normal or small non-tender gland; acute thyrotoxic symptoms during or months after amiodarone cessation Negative Elevated IL-6; normal or mild ESR rise Suppressed ( < 1 % < 1\% < 1% ); Colour Flow Doppler shows absent vascularity (hypovascular) • Oral prednisolone ( 40 mg/day 40\text{ mg/day} 40 mg/day tapered over 2–3 months); • Antithyroid drugs are ineffective

Acute Suppurative Thyroiditis Bacterial infection (Staph aureus, Strep pyogenes) secondary to haematogenous spread or congenital pyriform sinus fistula Unilateral severe neck pain, erythema, warmth, fluctuant tender mass, high swinging fevers, toxic appearance Negative Marked leukocytosis with neutrophilia; markedly elevated CRP/ESR Normal uptake with localized "cold" abscess defect • Urgent parenteral broad-spectrum IV antibiotics; • Ultrasound-guided aspiration or surgical drainage of abscess

  • 3. Management of Hyperthyroidism & Thyroid Storm
  • Pharmacotherapy: Thionamides

Carbimazole: First-line antithyroid drug in the UK (prodrug converted rapidly to active methimazole). Inhibits thyroid peroxidase (TPO), blocking iodination of tyrosine residues and coupling of iodotyrosines:

Titration Regimen: Start carbimazole 20–40 mg daily, titrating downwards every 4–6 weeks as free T4/T3 normalize, maintaining a euthyroid state for 12–18 months before trial of cessation (remission rate ~50%).

Block-and-Replace Regimen: Carbimazole 40 mg daily combined with levothyroxine 100 mcg daily once euthyroidism is achieved, continued for 12–18 months. Block-and-replace is strictly contraindicated in pregnancy .

Propylthiouracil (PTU): Inhibits TPO and also blocks peripheral 5'-deiodinase (inhibiting conversion of T4 to T3):

Indications: (1) First trimester of pregnancy (weeks 1–12): Carbimazole carries teratogenic risks of embryopathy, aplasia cutis congenita, and choanal atresia; PTU is preferred in early pregnancy, switching back to carbimazole in the second trimester to avoid maternal hepatotoxicity. (2) Thyroid storm. (3) Carbimazole intolerance/allergy.

Black Box Warning: Rare risk of severe, fulminant drug-induced hepatic necrosis.

Agranulocytosis: Most feared complication of thionamides ( 0.2 – 0.5 % 0.2\text{–}0.5\% 0.2 – 0.5% of patients; absolute neutrophil count < 0.5 × 10 9 / L < 0.5 \times 10^9/\text{L} < 0.5 × 1 0 9 / L ). Idiosyncratic; peaks within the first 3 months. Mandatory Patient Safety Advice: All patients must be explicitly counselled to stop the drug immediately and obtain an urgent full blood count (FBC) at the nearest emergency department if they develop a sore throat, mouth ulcers, unexplained fever, or systemic infection. Never initiate empirical antibiotics or wait for outpatient review without verifying the neutrophil count.

Radioiodine Therapy (131-I) & Surgery

Radioiodine-131: Emits beta particles destroying follicular tissue. First-line definitive therapy for toxic multinodular goitre, toxic solitary adenoma, and relapsed Graves'.

Absolute Contraindications: Pregnancy, breastfeeding, planned pregnancy within 6 months, and active moderate-to-severe Graves' orbitopathy (radioiodine releases thyroid autoantigens, worsening eye disease; if 131-I is used in mild orbitopathy, concurrent oral prednisolone prophylaxis is mandatory).

Total / Subtotal Thyroidectomy: Indicated for large compressive goitres, coexisting suspicious malignant nodules, patient refusal/contraindication to radioiodine, or severe Graves' orbitopathy. Complications: transient or permanent hypoparathyroidism (hypocalcaemia), recurrent laryngeal nerve palsy (hoarseness / bilateral airway compromise), haematoma.

Thyroid Storm (Accelerated Thyrotoxic Crisis)

Life-threatening hypermetabolic emergency with mortality up to 20–30%. Precipitated by infection, trauma, surgery, DKA, or radioiodine. Diagnosed clinically via the Burch-Wartofsky Point Scale (evaluating hyperpyrexia, agitation/coma, tachycardia/AF, congestive heart failure, and GI-hepatic dysfunction): Thyroid Storm 5-Pillar Emergency Protocol:

1. Beta-Blockade: IV Propranolol (1–2 mg IV slow push) or Esmolol → Controls adrenergic surge and blocks peripheral T4→T3 conversion

2. Antithyroid Drug: PTU (500–1000 mg loading, then 250 mg q4h PO/NG) → Inhibits de novo synthesis and peripheral conversion (superior to carbimazole)

3. Inorganic Iodine: Lugol's Iodine (or potassium iodide) given AT LEAST 1 HOUR AFTER PTU → Wolff-Chaikoff effect blocks release (giving iodine before PTU accelerates hormone synthesis!)

4. Corticosteroids: IV Hydrocortisone (100 mg q6h) → Treats relative adrenal insufficiency and inhibits peripheral T4→T3 conversion

5. Supportive / Cooling: External cooling blankets, paracetamol (avoid aspirin: displaces T4 from thyroid-binding globulin)